A population-based assessment of myocarditis after messenger RNA COVID-19 booster vaccination among adult recipients

Naveed, Zaeema; Li, Julia; Naus, Monika; Velásquez García, Héctor Alexander; Wilton, James; Janjua, Naveed Z.; Canadian Immunization Research Network Provincial Collaborative Network investigators

A population-based assessment of myocarditis after messenger RNA COVID-19 booster vaccination among adult recipients

Simple item page

Full item details

dc.contributor.author: Naveed, Zaeema; Li, Julia; Naus, Monika; Velásquez García, Héctor Alexander; Wilton, James; Janjua, Naveed Z.; Canadian Immunization Research Network Provincial Collaborative Network investigators
dc.date.accessioned: 2025-02-07T20:21:01Z
dc.date.available: 2025-02-07T20:21:01Z
dc.date.issued: 2023-06
dc.description.abstract - en: Objectives: We aimed to estimate the rate of myocarditis after the messenger RNA (mRNA) COVID-19 booster vaccination by vaccine type, age, and sex. Methods: We used data from the British Columbia COVID-19 Cohort, a population-based cohort surveillance platform. The exposure was a booster dose of an mRNA vaccine. The outcome was diagnosis of myocarditis during hospitalization or an emergency department visit within 7-21 days of booster vaccination. Results: The overall rate of myocarditis was lower for the booster dose (6.41, 95% confidence interval [CI]: 3.50-10.75) than the second dose (17.97, 95% CI: 13.78-23.04); (Rate ratiobooster vs dose-2 = 0.34, 95% CI: 0.17-0.61). This difference was more apparent for the mRNA-1273 vaccine type. After the second dose, the myocarditis rate in males was significantly lower for BNT162b2 than mRNA-1273 overall and among those aged 18-39 years. In contrast, after the booster dose, no significant differences between myocarditis and vaccine type was observed overall or within the specific age groups among males or females. Conclusion: Myocarditis after mRNA COVID-19 vaccines is a rare event. A lower absolute risk of myocarditis was observed after a booster dose of mRNA vaccine than the primary series second dose.
dc.identifier.doi: 10.1016/j.ijid.2023.03.027
dc.identifier.uri: https://open-science.canada.ca/handle/123456789/3412
dc.language.iso: en
dc.publisher - en: International Society for Infectious Diseases
dc.rights - en: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.rights - fr: Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
dc.rights.uri - en: https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.uri - fr: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
dc.subject - en: Health; Coronavirus diseases; Immunization
dc.subject - fr: Santé; Maladie à coronavirus; Immunisation
dc.subject.en - en: Health; Coronavirus diseases; Immunization
dc.subject.fr - fr: Santé; Maladie à coronavirus; Immunisation
dc.title - en: A population-based assessment of myocarditis after messenger RNA COVID-19 booster vaccination among adult recipients
dc.type - en: Article
dc.type - fr: Article
local.article.journaltitle - en: International Journal of Infectious Diseases
local.article.journalvolume: 131
local.pagination: 75-78
local.peerreview - en: Yes
local.peerreview - fr: Oui